Literature DB >> 8191241

Vasoactive intestinal polypeptide (VIP) secretion and refractory diarrhea in patients with AIDS or AIDS-related complex (ARC).

R Manfredi1, P Vezzadini, M P Fanti, F Chiodo.   

Abstract

Elevated plasma levels of vasoactive intestinal polypeptide (VIP) (as assessed by a radio-immunoassay), were found in 7/11 patients with AIDS or AIDS-related Complex (ARC), evaluated because of prolonged intractable diarrhea with either an infectious (6 cases) or a non-infectious (5 cases) etiology. Six subjects have been treated with the somatostatin analogue octreotide, which gave both a favourable clinical response and a significant reduction in plasma VIP concentrations. Evaluation of plasma VIP levels may provide a pathophysiological basis for explaining the efficacy of octreotide therapy in HIV-infected patients suffering from both infectious and non-infectious refractory diarrhea.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191241     DOI: 10.3109/00365549409008591

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  Delayed gastric emptying in human immunodeficiency virus infection: correlation with symptoms, autonomic function, and intestinal motility.

Authors:  P J Neild; K S Nijran; E Yazaki; D F Evans; D L Wingate; R Jewkes; B G Gazzard
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

2.  Effect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrhea.

Authors:  P J Neild; D F Evans; F D Castillo; R Newson; E T Yasaki; D L Wingate; B G Gazzard
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

3.  Plumbagin Prevents Secretory Diarrhea by Inhibiting CaCC and CFTR Channel Activities.

Authors:  Bo Yu; Xiaojuan Zhu; Xinyu Yang; Lingling Jin; Jia Xu; Tonghui Ma; Hong Yang
Journal:  Front Pharmacol       Date:  2019-10-09       Impact factor: 5.810

4.  VIP in HIV Diarrhea: Finding Links for the "Slim Disease".

Authors:  Arun Chaudhury
Journal:  Front Physiol       Date:  2015-12-23       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.